Latest Warning for Viekira Pak and Technivie Liver Damage

by | November 3rd, 2015

Viekira Pak™ and Technivie™ Liver Damage

In October, the U.S. Food and Drug Administration (FDA) issued a new warning regarding a potential link between liver damage and two medications used to treat Hepatitis C. Here are the latest details on the new warnings regarding Viekira Pak and Technivie.

The Warnings

The FDA approved Viekira Pak and Technivie in December of 2014. Within months, the agency began to receive reports of patients suffering serious liver damage while using these products.

The Wall Street Journal reports that since that time, as many as 26 patients have died or required extensive medical care—including organ transplants—in order to treat liver damage.

In response, the FDA has issued a statement asking that any patient who is using either of these drugs and experiences symptoms such as fatigue, nausea, vomiting, or yellowing of the eyes or skin, to speak with their physician immediately. These symptoms could be signs of liver damage. Patients have also been instructed to continue using the medications unless their doctor recommends otherwise.

Protecting Your Rights

If you’ve suffered liver damage as a result of using medications used to treat Hepatitis C, our Ohio drug injury lawyers are here to protect your rights. Our legal staff at Nurenberg, Paris, Heller & McCarthy encourage you to take a moment to look at these frequently asked questions about drug injury. You can also learn more about the options a drug injury attorney can provide by visiting our website.